You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 1, January 2, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Oncology, Other
 •Gastroenterology
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Genetics
 •Genetics, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis

Kenneth K. Tanabe, MD; Antoinette Lemoine, PharmD, PhD; Dianne M. Finkelstein, PhD; Hiroshi Kawasaki, MD, PhD; Tsutomu Fujii, MD, PhD; Raymond T. Chung, MD; Gregory Y. Lauwers, MD; Yakup Kulu, MD; Alona Muzikansky, MA; Darshini Kuruppu, PhD; Michael Lanuti, MD; Jonathan M. Goodwin, BS; Daniel Azoulay, MD, PhD; Bryan C. Fuchs, PhD

JAMA. 2008;299(1):53-60.

Context  Overexpression of epidermal growth factor (EGF) in the liver induces transformation to hepatocellular carcinoma in animal models. Polymorphisms in the EGF gene modulate EGF levels.

Objective  To assess the relationship among human EGF gene single-nucleotide polymorphism, EGF expression, and risk of hepatocellular carcinoma.

Design, Setting, and Participants  Molecular mechanisms linking the 61*G allele polymorphism to EGF expression were examined in human hepatocellular carcinoma cell lines and human liver tissue. A case-control study involving 207 patients with cirrhosis was conducted at the Massachusetts General Hospital (1999-2006) and a validation case-control study involving 121 patients with cirrhosis was conducted at Hôpital Paul Brousse (1993-2006). Restriction fragment-length polymorphism was used to determine the EGF gene polymorphism genotype. Logistic regression analysis was used to assess the association between the EGF polymorphism and hepatocellular carcinoma risk.

Main Outcome Measures  Mechanisms by which the EGF gene polymorphism modulates EGF levels and associations among EGF gene polymorphism, EGF levels, and hepatocellular carcinoma.

Results  Transcripts from the EGF 61*G allele exhibited more than a 2-fold longer half-life than those from the 61*A allele, and EGF secretion was 2.3-fold higher in G/G hepatocellular carcinoma cell lines than A/A cell lines. Serum EGF levels were 1.8-fold higher in G/G patients than A/A patients, and liver EGF levels were 2.4-fold higher in G/G patients than A/A patients. Among the 207 patients with cirrhosis in the Massachusetts study population, 59 also had hepatocellular carcinoma. Analysis of the distribution of allelic frequencies revealed that there was a 4-fold odds of hepatocellular carcinoma in G/G patients compared with A/A patients in the Massachusetts study population (odds ratio, 4.0; 95% confidence interval [CI], 1.6-9.6; P = .002). Logistic regression analysis demonstrated that the number of copies of G was significantly associated with hepatocellular carcinoma after adjusting for age, sex, race, etiology, and severity of cirrhosis (G/G or A/G vs A/A; hazard ratio, 3.49; 95% CI, 1.29-9.44; P = .01). The significant association was validated in the French patients with alcoholic cirrhosis and hepatocellular carcinoma.

Conclusion  The EGF gene polymorphism genotype is associated with risk for development of hepatocellular carcinoma in liver cirrhosis through modulation of EGF levels.


Author Affiliations: Division of Surgical Oncology (Drs Tanabe, Kawasaki, Fujii, Kulu, Kuruppu, and Fuchs), Department of Biostastistics (Dr Finklestein and Ms Muzikansky), Gastrointestinal Unit, Department of Medicine (Dr Chung), Department of Pathology (Dr Lauwers), and Division of Thoracic Surgery (Dr Lanuti and Mr Goodwin), Massachusetts General Hospital, Harvard Medical School, Boston; and Biochimie et Biologie Moléculaire (Dr Lemoine), Centre de Chirurgie Hépatobiliaire (Dr Azoulay), Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris; Université Paris-Sud/XI; Faculté de Pharmacie, Châtenay-Malabry; Inserm, U602; Villejuif, France. Drs Lemoine, Finkelstein, and Kawasaki contributed equally to this study.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sex-specific association of epidermal growth factor gene polymorphisms with acute respiratory distress syndrome
Sheu et al.
Eur Respir J 2009;33:543-550.
ABSTRACT | FULL TEXT  

A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome
Lanuti et al.
Clin. Cancer Res. 2008;14:3216-3222.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.